In order to improve its delivery and therapeutic efficacy in treating HER2-positive breast cancer with less side effects [247, 248], Ma et al. [249] designed a nanorobot called HApt-tFNA, in which he anchored an anti-HER2 inducer (HApt) to a tetrahedral framework nucleic acid (tFNA). The gene discussed is ERBB2; the disease is breast cancer.